Renal Cell Carcinoma
Conditions
Interventions
Arm of Sunitinib 2-week on/ 1-week off Sunitinib 50 mg/day PO 2 weeks followed by 1 week rest. The patients with Grade 3 and more or required interruption due to investigators judge, are interrupted
Sponsors
Osaka University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: – Histologically confirmation or clinically diagnosis of renal cell carcinoma Measurable disease at least 1 site according to RECIST criteria are required in CT images Life expectancy of > 12 weeks Signed and dated informed consent of document indicating that the patient but representative has been informed of all pertinent aspects of the trial prior to enrollment
Exclusion criteria
Exclusion criteria: Diagnosis of any secondary malignancy Patients who are judged by an investigator to be inappropriate for this study for any other reason
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Treatment discontinuation rate due to unacceptable toxicities and relative dose intensity within 6 weeks (within 1 course) Duration of treatment and progression free-survival | — |
Secondary
| Measure | Time frame |
|---|---|
| –Objective response rate –Quality of life | — |
Countries
Japan
Contacts
Public ContactMotohide Uemura
Osaka University Graduate School of Medicine Department of Organ Specific Regulation (Urology)
Outcome results
None listed